Refanezumab

Refanezumab (GSK249320) is a monoclonal antibody designed for the recovery of motor function after stroke.[1]

Refanezumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
Targetmyelin-associated glycoprotein
Clinical data
Other namesGSK249320
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6608H10156N1732O2064S44
Molar mass148.3 kg/mol g·mol−1

This drug was developed by GlaxoSmithKline.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.